C4 Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview

C4 Therapeutics

31/07/2023 14:47

* C4 Therapeutics Inc  CCCC.OQ   CCCC.O  is expected to show
a
fall in quarterly revenue when it reports  results on August 2
(estimated). 
    * The Watertown Massachusetts-based  company is expected to
report
 a 53.5% decrease in revenue to $6.439 million from $13.83
million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for C4 Therapeutics Inc
is
for a loss of 69 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for C4
Therapeutics
Inc is $14​, above​ its last closing price of $3.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.73       -0.75      -0.71     Beat    4.8
 Dec. 31 2023  -0.73       -0.74      -0.77     Missed  -3.5
 Sep. 30 2022  -0.65       -0.67      -0.65     Beat    3​
 Jun. 30 2022  -0.70       -0.69      -0.56     Beat    19.2
 ​​Mar.        -0.56       -0.58      -0.65     Missed  -12.3
 31 2022                                                
 Dec. 31 2021  -0.58       -0.58      -0.31     Beat    46.8​
 Sep. 30 2021  -0.57       -0.59      -0.51     Beat    13.8
 Jun. 30 2021  -0.59       -0.59      -0.51     Beat    13.6
 This summary was machine generated July 31 at 13:47 GMT.  All
figures in US dollars  unless otherwise stated